-The Times of India The Supreme Court on Monday rejected pharma giant Novartis AG's plea to preserve its patent over a life-saving cancer drug, Glivec, drawing a huge sigh of relief from thousands of patients in India and in dozens of developing countries as the fear of an almost 15-fold escalation of drug costs receded. It is the biggest setback for multinational pharma companies, which have been denied patent protection...
More »SEARCH RESULT
Total Matching Records found : 89
SC’s Glivec ruling setback to foreign pharma firms -Vidya Krishnan and CH Unnikrishnan
-Live Mint SC rejects Novartis's patent plea for Glivec, says it does not meet any standard of novelty or inventiveness In a landmark judgement, India's apex court rejected Swiss drug maker Novartis AG's legal challenge aimed at securing a patent for blockbuster anti-cancer drug imatinib mesylate, branded Glivec in the country. The verdict, which is seen as a setback to multinational pharmaceutical companies operating in India, may influence a rash of pending disputes...
More »Novartis case may make foreign firms more wary of Indian drugs market-Ravi Ananthanarayanan
-Live Mint SC judgement may not open a floodgate of revenues for local pharma firms; nevertheless, it is a psychological win The Supreme Court has dismissed an appeal by Novartis AG to revoke denial of a patent to its cancer drug Glivec. The judgement is important because multinational companies (MNCs) can be denied patent protection on improved drugs unless they can prove the medication has better efficacy. Although this decision will displease...
More »Artful claims can’t decide patent law: court-J Venkatesan
-The Hindu The law of patent in India could not be developed on the artful drafting of claims by companies rather than on the intrinsic worth of Invention, the Supreme Court has ruled, rejecting Novartis' claim for patent for its cancer drug. A Bench of Justices Aftab Alam and Ranjana Desai said, "We certainly do not wish the law of patent... to develop on the lines where there may be a vast...
More »Landmark verdict gives big boost to cancer patients-J Venkatesan
-The Hindu Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new Invention. The judgment allows suppliers to continue making generic copies of Swiss firm Novartis' Glivec or Gleevec, which has been shown to...
More »
